Abstract
The dynamic cross-talk between bench – based research and clinical practice is the fundamental characteristic of modern oncology. Colorectal cancer, the second most common cause of cancer – related death in the Western world, is the paradigm of the revolutionary use of targeted sophisticated therapies. The continuous unraveling of the molecular identity of signaling pathways that govern sub-cellular decisions reveals candidate targets. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) signaling pathways are considered major tumor-promoting cascades. Three monoclonal antibodies have been approved for the management of metastatic colorectal cancer. Cetuximab and panitumumab target the EGFR-signaling pathway, inhibiting the aberrant transduction of tumor – proliferating signals, as well as promoting tumor cell apoptosis. Bevacizumab is the first antibody inhibiting VEGF – driven formation of new blood vessels, a critical component of tumor metastasis. Randomized clinical trials in patients with colorectal cancer have shown significant clinical benefit and tolerable toxicity with the use of these antibodies. At the era of clinical bioinformatics, better selection of patient subpopulations with tumor-over-expressing specific clinical biomarkers could result in significant enhancement of signal transduction targeting success. This review discusses characteristics of cancer-associated signaling, describes the mechanism of action of the three monoclonal antibodies, focusing on their current role in the management of colorectal cancer.
Keywords: Colorectal cancer, signaling, monoclonal antibodies, cetuximab, panitumumab, bevacizumab
Current Signal Transduction Therapy
Title: Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine
Volume: 4 Issue: 1
Author(s): Haralabos Kalofonos and Petros D. Grivas
Affiliation:
Keywords: Colorectal cancer, signaling, monoclonal antibodies, cetuximab, panitumumab, bevacizumab
Abstract: The dynamic cross-talk between bench – based research and clinical practice is the fundamental characteristic of modern oncology. Colorectal cancer, the second most common cause of cancer – related death in the Western world, is the paradigm of the revolutionary use of targeted sophisticated therapies. The continuous unraveling of the molecular identity of signaling pathways that govern sub-cellular decisions reveals candidate targets. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) signaling pathways are considered major tumor-promoting cascades. Three monoclonal antibodies have been approved for the management of metastatic colorectal cancer. Cetuximab and panitumumab target the EGFR-signaling pathway, inhibiting the aberrant transduction of tumor – proliferating signals, as well as promoting tumor cell apoptosis. Bevacizumab is the first antibody inhibiting VEGF – driven formation of new blood vessels, a critical component of tumor metastasis. Randomized clinical trials in patients with colorectal cancer have shown significant clinical benefit and tolerable toxicity with the use of these antibodies. At the era of clinical bioinformatics, better selection of patient subpopulations with tumor-over-expressing specific clinical biomarkers could result in significant enhancement of signal transduction targeting success. This review discusses characteristics of cancer-associated signaling, describes the mechanism of action of the three monoclonal antibodies, focusing on their current role in the management of colorectal cancer.
Export Options
About this article
Cite this article as:
Kalofonos Haralabos and Grivas D. Petros, Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine, Current Signal Transduction Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157436209787048720
DOI https://dx.doi.org/10.2174/157436209787048720 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
18F-FDG PET/CT Demonstrates Efficacy and Limitations of Hepatic Arterial Infusion Chemotherapy for Treating Colorectal Liver Metastases
Current Radiopharmaceuticals Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets
Current Pharmaceutical Design Omega-3 Polyunsaturated Fatty Acids and Cancer
Anti-Cancer Agents in Medicinal Chemistry Homology Modeling of Human Nicotinamide/Nicotinic Acid Mononucleotide Adenylyltransferase 2: Insights into Isoenzyme-Specific Differences Using Molecular Docking Simulatons
Letters in Drug Design & Discovery Sam68 Promotes the Progression of Human Breast Cancer through inducing Activation of EphA3
Current Cancer Drug Targets Light-at-Night-Induced Circadian Disruption, Cancer and Aging
Current Aging Science Editorial (Thematic Issue: Development of Biomarkers in Tumors of Digestive System Part II)
Anti-Cancer Agents in Medicinal Chemistry Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology Thymidine Phosphorylase and Fluoropyrimidines Efficacy: A Jekyl and Hyde Story
Current Medicinal Chemistry - Anti-Cancer Agents Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors
Current Topics in Medicinal Chemistry Analysis of the Concordance in the EGFR Pathway Status Between Primary Tumors and Related Metastases of Colorectal Cancer Patients:Implications for Cancer Therapy
Current Cancer Drug Targets Transmembrane Protein 166 and its Significance
Protein & Peptide Letters Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Role of Alterations in the Apoptotic Machinery in Sensitivity of Cancer Cells to Treatment
Current Pharmaceutical Design Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?
Current Pharmaceutical Design Alginate Based Nanocarriers for Drug Delivery Applications
Current Pharmaceutical Design Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies
Current Drug Targets Biomarkers of Protein Oxidation in Human Disease
Current Molecular Medicine Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science